Kronos Bio/KRON

$1.27

11.4%
-
1D1W1MYTD1YMAX

About Kronos Bio

Kronos Bio, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics that target the dysregulated transcription that causes cancer and other serious diseases. It focuses on advancing two investigational compounds in clinical trials for patients with cancer. The Company’s product engine includes its proprietary small molecule microarray (SMM) screening platform, which provides the capability to map and target transcription regulatory networks (TRNs) in a differentiated manner to enable discovery of novel compounds and improve its ability to discover and optimize clinical development candidates. Its pipeline includes KB-0742 and Lanraplenib. KB-0742 is an oral cyclin dependent kinase 9 (CDK9) inhibitor for the treatment of MYC-amplified and other transcriptionally addicted solid tumors. Lanraplenib is a small molecule selective inhibitor targeting spleen tyrosine kinase (SYK), a critical node in a dysregulated TRN within acute myeloid leukemia (AML).

Ticker

KRON

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Norbert Bischofberger

Employees

99

Headquarters

San mateo, United States

Kronos Bio Metrics

BasicAdvanced
$62.4M
Market cap
-
P/E ratio
-$2.08
EPS
1.79
Beta
-
Dividend rate

What the Analysts think about Kronos Bio

Analyst Ratings

Majority rating from 3 analysts.
Buy

Price Targets

Average projection from 2 analysts.
234.65% upside
High $6.00
Low $2.50
$1.27
Current price
$4.25
Average price target

Kronos Bio Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-3,477.77% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$900K
-50%
Net income
$-31.3M
5.39%
Profit margin
-3,477.77%
110.77%

Kronos Bio Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 5.37%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.56
-$0.46
-$0.52
-$0.54
-
Expected
-$0.59
-$0.45
-$0.46
-$0.51
-$0.53
Surprise
-4.44%
3.37%
13.04%
5.37%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Kronos Bio stock

Buy or sell Kronos Bio stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing